Case report on a 32‑year‑old female with elevated serum creatinine levels and primary Sjögren's syndrome‑chronic interstitial nephritis
- Yi Yu
- Bojun Zheng
- Jing Huang
- Dingwei Deng
- Xiaoli Jing
- Published online on: October 1, 2019 https://doi.org/10.3892/etm.2019.8073
- Pages: 4363-4367
Copyright: © Yu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
PSS is a chronic inflammatory, multi-systemic autoimmune disease (1) that may involve various organs, but commonly results in renal damage (40–50% of cases) (2). Although the condition may be life-threatening in severe cases, the early clinical symptoms of renal lesions in such cases are frequently atypical, and may hence be overlooked by clinicians. The present study reports on the clinical and pathological features, as well as the laboratory and immunofluorescence data of a patient who initially presented with chronic renal insufficiency, but was finally diagnosed with PSS.
A 32-year-old female presented at our hospital The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangzhou, China) in June 2017 with a 1-year history of elevated serum creatinine levels and a 6-month history of mild pain in the waist and leg. For >6 months prior to admission, the patient did not experience any symptoms/complaints including fever, dizziness, headache, cough, expectoration, nausea, vomiting, abdominal pain, diarrhea, hematuria, frothy urine, eyelid, facial or lower extremity edema. The patient had undergone a routine medical examination in June 2018 and ignored the result of blood creatinine levels of 229.0 µmol/l (normal range, 53–98 µmol/l). Thereafter, the patient was admitted to the First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine (Guangzhou, China) in August 2017 for low back pain, and the laboratory test results indicated a creatinine level of 242.0 µmol/l, urea levels of 11.2 mmol/l (2.86–7.14 mmol/l), parathyroid hormone levels of 73.1 pmol/l (1–10.5 pmol/l), and total cholesterol level of 6.3 mmol/l (3–5.2 mmol/l); the other symptoms/complaints were similar to those observed previously. Furthermore, the presence of kidney stones was noted in a physical examination 1 year previously. The patient had no history of tuberculosis, type 2 diabetes, steroid use, traditional homeopathic remedies or herbal medications.
On admission to our hospital, the patient weighed 47.0 kg, had a body height of 160.0 cm and a body mass index of 18.3 kg/m2. The patient's blood pressure and pulse were recorded as 123/77 mmHg and 86 beats/min. The patient was mildly anemic, but did not have any goiter or clinically palpable lymph nodes. Furthermore, no gynecomastia, striae or evidence of pruritus was noted. The patient's visual field was normal and no papilledema was detected. The other physical findings were unremarkable.
The laboratory test results on admission and during the follow-up period are presented in Table I. Twenty-four-hour urine output monitoring indicated stable fluctuations from 2,200 to 3,100 ml, and a urine osmolarity of 169.0 mOsm/kg H2O (normal range, 280.0–310.0 mOsm/kg H2O) was noted. Based on these results, tests for antinuclear antibodies (ANA; 1:100 granular pattern), along with other tumor, rheumatic disease and immune system markers, were performed, but the results were negative. Thus, the patient was initially diagnosed with severe chronic interstitial nephritis and chronic kidney disease stage IV. As the patient had a long history of xerostomia and dry eye syndrome, the presence of Sjogren's syndrome was suspected. To confirm this hypothesis, a kidney biopsy was performed. Routine clinical examination by specialist including comprehensive light microscopy, immunofluorescence and electron microscopy examination indicated the presence of severe chronic interstitial nephritis (Figs. 1–3), consistent with the biochemical indicators. Furthermore, kidney ultrasonography was performed (Fig. 4), which indicated an abnormal echo of the bilateral kidneys (consistent with sonographic changes in chronic kidney disease), as well as multiple calculi or calcifications in the bilateral kidneys. In addition, salivary gland scintigraphy indicated a decrease in left parotid uptake tracer function, as well as impairment of secretion and excretion. However, no abnormal uptake, secretion or excretion were observed in the right parotid gland and bilateral submandibular glands (Fig. 5).
Immunofluorescence to clarify diagnosis. magnification, ×400. κ, negative; λ, negative; amyloid A, negative; fibrin, negative; albumin, reabsorbed droplets visible in the renal tubules; IgG1, negative; IgG2, negative; IgG3, negative; IgG4, negative; phospholipase A2 receptor, negative; hepatitis B surface antigen, negative; hepatitis B e antigen, negative; hepatitis B core antigen, negative; C4d, glomeruli in the kidney (−); thrombospondin type 1 domain containing 7A, negative.
(A) Hematoxylin-eosin staining indicated extensive renal interstitial fibrosis with scattered inflammatory cell infiltration; (B) periodic acid-Schiff staining revealed sclerosis of the glomeruli. magnification, ×100. (C) periodic Schiff-methenamine staining indicates that the capillary loops are open and the basement membrane is not thickened; (D) Masson staining reveals no apparent deposition of complexed erythropoietin in the glomeruli. magnification, ×400.
Abnormal echo of the bilateral kidneys (consistent with sonographic changes in chronic kidney disease) indicates multiple calculi or calcifications in the kidneys.
Bilateral parotid gland and submandibular gland. (A) Dynamic imaging of maxillofacial blood flow in the bilateral parotid gland and submandibular gland. (B) Line chart of radioactive distribution. On dynamic imaging of maxillofacial blood flow performed via intravenous injection of the imaging agent, no abnormal radioactivity distribution in the bilateral parotid gland and submandibular gland was observed. In brief, the salivary gland function was dynamically developed for 24 min, vitamin C tablets were ingested after 18 min, and bilateral and anteroposterior plane imaging was performed after gargling, along with delayed flank imaging of the salivary glands. No delay in bilateral parotid and submandibular gland radioactivity uptake was observed, although the right parotid gland and bilateral submandibular gland radioactivity uptake were abnormal but approximately symmetrical. After ingesting vitamin C tablets at 18 min, no obvious radioactivity clearance in the bilateral parotid gland or bilateral submandibular gland, or partial accumulation of radioactivity in the oral cavity was noted. The two sides of the parotid gland and submandibular gland were clearly developed and the distribution of the bilateral parotid gland radioactivity was sparse. Minimal radioactivity distribution was noted in the oral cavity, although this decreased after gargling and delayed imaging.
Based on these results, the patient was diagnosed with severe chronic interstitial nephritis, stage IV chronic kidney disease, PSS and anemia due to chronic kidney disease. To address the PSS-associated chronic interstitial nephritis, the patient was subjected to continuous treatment with half-dose glucocorticoid. Given the presence of PSS, initial treatment involved prednisone (0.5 mg/kg/day), with subsequent slow tapering to 0.5–0.25 mg/kg/day, followed by addition of cyclophosphamide at doses of 800 mg/month over the next 6 months. A 12-month follow-up examination indicated significant improvement (Table I).
PSS is a common condition involving various organs. The detection of autoimmune diseases with the exocrine gland as the target organ has improved with the advancements in detection methods and a better understanding of the disease (3). Accordingly, the rate of early detection and diagnosis in cases with PSS has also significantly increased. In particular, kidney damage as a result of PSS has been receiving an increasing amount of attention (4). PSS-associated renal damage may be asymptomatic or may present only as an electrolyte disorder. Furthermore, as the clinical manifestations of the disease in these patients are varied (including proteinuria, simple hematuria, combined hematuria and proteinuria, or nephrotic syndrome and renal insufficiency), and the prognosis is good, only a small number of clinical studies have focused on this condition thus far (5). Although the incidence of renal damage in PSS was previously thought to be low, recent studies indicated a rate of as high as 33.5% (2,6,7). Most cases exhibit renal tubular dysfunction, particularly involving the distal renal tubule. Prominent manifestations include distal renal tubular acidosis, renal diabetes insipidus and urinary concentration dysfunction, followed by glomerulonephritis and partial renal insufficiency (8). As there are no uniform diagnostic criteria for assessing renal damage in PSS patients with mild or no symptoms, the condition is overlooked in most of such cases. Only a small number of such patients exhibit renal failure at the time of visit, and hence, early diagnosis is particularly important.
It is recommended that patients with PSS are screened at least twice a year, including urine protein, urine pH, urine osmotic pressure, serum creatinine, glomerular filtration rate and electrolyte levels (9). The European League Against Rheumatism Sjogren's syndrome disease activity index may be used to assess renal disease activity during follow-up (10). Renal biopsy should be promptly performed, if required, in such cases, and the cause and extent of renal lesions may be determined via renal pathology examinations (11).
With regard to treatment, individualized therapy may be suitable, based on the patient's clinical manifestation and the type of renal damage. At present, treatment may be divided into local replacement therapy and systemic treatment (4,12). The present case was managed by low-dose hormone therapy and regular follow-up. The renal function was stable and did not deteriorate during follow-up, which indicated that the treatment was effective. However, it may be necessary to perform further detailed studies in order to better understand the disease mechanism, and large-sample multicenter randomized controlled trials should be performed to assess the efficacy and safety of drugs including hormones and immunosuppressants in these patients with different types of renal damage.
In the clinical setting, patients with kidney stones and renal insufficiency are frequently encountered, and it is likely that kidney dysfunction has led to stone obstruction in these cases. However, it is recommended that clinicians should also consider systemic diseases, including tumors, rheumatism and immune diseases, in such patients. Accordingly, careful assessment of the relevant medical history may help improve the diagnostic accuracy and avoid kidney failure.
No funding was received.
Availability of data and materials
The data used for the preparation of the manuscript, including all relevant raw data, are freely available to any scientist wishing to use them for non-commercial purposes, without breaching participant confidentiality. Available from the corresponding author upon reasonable request.
YY, BZ and JH prepared the manuscript, made substantial contributions to the design of the work and to revise it critically for important intellectual content. XJ and DD critically reviewed the manuscript for important intellectual content and approved the final manuscript. All authors read and approved the final manuscript.
Ethics approval and consent to participate
The patient consented to participate and provided written informed consent.
Patient consent for publication
The patient agreed to the publication of their data and images.
The authors declare that they have no competing interests.
Nilsson AM, Tufvesson E, Hesselstrand R, Olsson P, Wollmer P and Mandl T: Increased B-cell activating factor, interleukin-6, and interleukin-8 in induced sputum from primary Sjögren's syndrome patients. Scand J Rheumatol. 48:149–156. 2019. View Article : Google Scholar : PubMed/NCBI
Jain A, Srinivas BH, Emmanuel D, Jain VK, Parameshwaran S and Negi VS: Renal involvement in primary Sjögren's syndrome: A prospective cohort study. Rheumatol Int. 38:2251–2262. 2018. View Article : Google Scholar : PubMed/NCBI
Brito-Zerón P and Ramos-Casals M; EULAR-SS task force group, : Advances in the understanding and treatment of systemic complications in Sjögren's syndrome. Curr Opin Rheumatol. 26:520–527. 2014. View Article : Google Scholar : PubMed/NCBI
Flores-Chavez A, Kostov B, Solans R, Fraile G, Maure B, Feijoo-Massó C, Rascón FJ, Pérez-Alvarez R, Zamora-Pasadas M, García-Pérez A, et al: Severe, life-threatening phenotype of primary Sjögren's syndrome: Clinical characterisation and outcomes in 1580 patients (GEAS-SS Registry). Clin Exp Rheumatol. 36 (Suppl 112):S121–S129. 2018.
Zou Y, Ling G, Tian J, Chen J and Ge Y: Research progress in renal injury relevant to primary Sjögren's syndrome. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 43:320–326. 2018.(In Chinese). PubMed/NCBI
Weiner SM: Renal involvement in connective tissue diseases. Dtsch Med Wochenschr. 143:89–100. 2018.(In German). PubMed/NCBI
Liu X, Li X, Li X, Li Z, Zhao D, Liu S, Zhang M, Zhang F, Zhu P, Chen J, et al: The efficacy and safety of total glucosides of peony in the treatment of primary Sjögren's syndrome: A multi-center, randomized, double-blinded, placebo-controlled clinical trial. Clin Rheumatol. 38:657–664. 2019. View Article : Google Scholar : PubMed/NCBI
Kobayashi I, Okura Y, Ueki M, Tozawa Y, Takezaki S, Yamada M and Ariga T: Evaluation of systemic activity of pediatric primary Sjögren's syndrome by EULAR Sjögren's syndrome disease activity index (ESSDAI). Mod Rheumatol. 29:130–133. 2019. View Article : Google Scholar : PubMed/NCBI
Jasiek M, Karras A, Le Guern V, Krastinova E, Mesbah R, Faguer S, Jourde-Chiche N, Fauchais AL, Chiche L, Dernis E, et al: A multicentre study of 95 biopsy-proven cases of renal disease in primary Sjögren's syndrome. Rheumatology (Oxford). 56:362–370. 2017.PubMed/NCBI
Meiners PM, Vissink A, Kroese FG, Spijkervet FK, Smitt-Kamminga NS, Abdulahad WH, Bulthuis-Kuiper J, Brouwer E, Arends S and Bootsma H: Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study). Ann Rheum Dis. 73:1393–1396. 2014. View Article : Google Scholar : PubMed/NCBI